| Last week, the Trump administration unveiled a new proposal that aims to reduce reimbursement for medicines administered to seniors under the Medicare Part B benefit to an amount pegged to the average price paid in foreign industrial nations. It would link U.S. prices to an International Pricing Index (IPI) based on sixteen other countries. |
|
| It’s a move that could entirely reshape the way pharma and biotech think about their business model in the U.S. |
|
| We sat down with Archbow Consulting’s international pricing expert to better understand each brand's risk under the IPI. Read the article for more information on: |
|
| • |
How the proposed IPI compares to International Reference Pricing (IRP) |
| • |
Illustrative case studies on the proposed methodology |
| • |
If price erosion in countries around the world could impact your brand’s price |
| • |
How you can prepare today for the downstream impact of the IPI |
|
